Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-A1 in Healthy Young Adults
NCT07616934Phase 1Recruiting
- Sponsor
- Vaxcyte
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VAX-A1 in Group A streptococcal infection (4 arms), sponsored by Vaxcyte. Primary endpoints: Frequency of solicited local reactions at 7 days, Frequency of solicited systemic adverse events at 7 days and 6 more. Started Jun 2026; status: recruiting.
02
Drugs
VAX-A1
03
Conditions
Group A streptococcal infection
Beyond the preview
Go deeper on NCT07616934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616934.